Table 4.
Results of pairwise and network meta-analysis for strength improvement in different follow-ups
| At 1 st month | CS | 0.15 (-18.93 to 19.50) | NA | 12.04 (-6.84 to 32.17) | 9.37 (-18.44 to 38.14) |
| 3.67 (-12.57 to 19.27) | AB | 0.07 (-30.72 to 31.67) | -2.39 (-33.30 to 28.09) | NA | |
| 6.49 (-14.06 to 26.42) | 2.85 (-17.27 to 23.45) | PL | -2.72 (-33.63 to 28.51) | 3.50 (-16.99 to 23.32) | |
| 7.81 (-7.10 to 24.68) | 4.13 (-13.10 to 23.66) | 1.47 (-18.44 to 23.02) | PRP | NA | |
| 10.02 (-10.55 to 29.33) | 6.70 (-15.79 to 26.87) | 3.49 (-13.23 to 19.86) | 2.21 (-21.30 to 22.57) | BT | |
| At 3 rd month | AB | 0.45 (-22.29 to 23.25) | 2.86 (-20.62 to 26.96) | 6.80 (-8.10 to 21.81) | NA |
| 1.46 (-12.01 to 15.06) | PRP | 2.25 (-19.86 to 25.35) | 4.28 (-10.58 to 19.90) | NA | |
| 4.89 (-10.91 to 20.68) | 3.36 (-12.75 to 19.00) | PL | NA | 2.89 (-11.24 to 18.63) | |
| 5.47 (-5.46 to 17.04) | 4.06 (-6.89 to 15.86) | 0.93 (-13.20 to 16.31) | CS | 4.15 (-16.96 to 25.30) | |
| 8.00 (-8.23 to 26.36) | 6.62 (-9.30 to 23.54) | 3.49 (-7.92 to 15.96) | 2.79 (-12.60 to 18.02) | BT |
Note: Treatments are ranked according to their SUCRA. The comparative therapeutic efficacies are reported as unstandardized mean difference with 95% credible intervals (in parentheses). The comparison between the treatments should be read from left to right. The network meta-analysis results are presented in the left lower (by comparing columns with rows), and the pairwise meta-analysis results are presented in the right upper (by comparing rows with columns).
Abbreviations: CS, corticosteroid; AB, autologous blood; BT, botulinum toxin; PRP, platelet-rich plasma; PL, placebo